J.P. Morgan Sticks to Their Buy Rating for Innovent Biologics (IVBXF)
In a report released on March 28, Yang Huang from J.P. Morgan maintained a Buy rating on Innovent Biologics (IVBXF – Research Report), with a ...
Nasdaq2d
Innovent Biologics Gets NMPA Breakthrough Therapy Designation For IBI363 In Melanoma
(RTTNews) - Innovent Biologics Inc. (IVBXF.OB) announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted Breakthrough Therapy ...
Pharmabiz1d
China NMPA grants breakthrough therapy designation for Innovent’s PD-1/IL-2a-bias bispecific antibody fusion protein, IBI363 in melanoma
San Francisco, US Tuesday, April 1, 2025, 15:00 Hrs [IST] ...
GlobalData on MSN8d
Innovent Biologics doses first subject in trial of ovarian cancer therapy
Innovent Biologics has dosed the first subject in the randomised Phase III HeriCare-Ovarian01 trial of IBI354 for treating ...
Pharmabiz8d
Innovent Biologics begins patient dosing in phase 3 study of IBI354 for platinum-resistant ovarian cancer
Innovent Biologics begins patient dosing in phase 3 study of IBI354 for platinum-resistant ovarian cancer: San Francisco Tuesday, March 25, 2025, 18:00 Hrs [IST] Innovent Biologic ...
Vietnam Investment Review on MSN9d
Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 for Platinum-resistant Ovarian Cancer
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality ...
Innovent Biologics: Innovent Announces 2024 Annual Results and Business Updates
First-ever positive profit, entering a new era of growth and global innovation SAN FRANSISCO and SUZHOU, China, March 26, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: ...
Yahoo Finance2d
Innovent Receives NMPA Breakthrough Therapy Designation for IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Melanoma
SAN FRANCISCO and SUZHOU, China, March 30, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that ...
Medindia2d
Innovent Receives NMPA Breakthrough Therapy Designation for IBI363 (PD-1/IL-2a-bias Bispecific Antibody Fusion Protein) in Melanoma
PR Newswire SAN FRANCISCO and SUZHOU, China, March 30, 2025 SAN FRANCISCO and SUZHOU, China, March 30, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a ...
Yahoo Finance2d
Innovent Receives NMPA Breakthrough Therapy Designation for IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Melanoma
SAN FRANCISCO and SUZHOU, China, March 30, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...